Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: A case study of orally available novel inhibitors of anaplastic lymphoma kinase

Drug Metabolism and Disposition

Volumn 43, Issue 1, 2015, Pages 54-62

  Yamazaki, Shinji ^a   Lam, Justine L ^a   Zou, Helen Y ^a   Wang, Hui ^a   Smeal, Tod ^a   Vicini, Paolo ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINO 12 FLUORO 2,10,16 TRIMETHYL 15 OXO 10,15,16,17 TETRAHYDRO 2H 8,4 (AZENO)PYRAZOLO[4,3 H][2,5,11]BENZOXADIAZACYCLOTETRADECINE 3 CARBONITRILE; 7 AMINO 12 FLUORO 2,10,16 TRIMETHYL 15 OXO 10,15,16,17 TETRAHYDRO 2H 8,4 (METHENO)PYRAZOLO[4,3 H][2,5,11]BENZOXADIAZACYCLOTETRADECINE 3 CARBONITRILE; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; CRIZOTINIB; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4 ANAPLASTIC LYMPHOMA KINASE FUSION PROTEIN; HYBRID PROTEIN; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; 7-AMINO-12-FLUORO-2,10,16-TRIMETHYL-15-OXO-10,15,16,17-TETRAHYDRO-2H-8,4-(METHENO)PYRAZOLO(4,3-H)(2,5,11)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE; ANTINEOPLASTIC AGENT; MACROCYCLIC LACTAM; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER MODEL; COMPARATIVE EFFECTIVENESS; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; ELM4 ALK GENE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; FUSION GENE; GENE MUTATION; IN VIVO STUDY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; OSMOTIC PUMP; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CARCINOMA, NON-SMALL-CELL LUNG; DRUG SCREENING; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ECHINODERMATA; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; LACTAMS, MACROCYCLIC; LUNG NEOPLASMS; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; MODELS, BIOLOGICAL; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919683812     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.061143     Document Type: Article

References (27)

1. Arnedos M, Vielh P, Soria JC, and Andre F (2014) The genetic complexity of common cancers and the promise of personalized medicine: is there any hope? J Pathol 232:274-282.
2. Beal S and Sheiner L (1992) NONMEM user guides. NONMEM project group, University of California at San Francisco, San Francisco, CA.
3. Casaluce F, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F, and Gridelli C (2013) ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Targeted Oncology 8:55-67.
4. Chien JY, Friedrich S, Heathman MA, de Alwis DP, and Sinha V (2005) Pharmacokinetics/ Pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J 7:E544-E559.
5. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, and Haruta H, et al.; ALK Lung Cancer Study Group (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363:1734-1739.
6. Cohen A (2008) Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies. Clin Pharmacokinet 47:373-381.
7. Derendorf H, Lesko LJ, Chaikin P, Colburn WA, Lee P, Miller R, Powell R, Rhodes G, Stanski D, and Venitz J (2000) Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol 40:1399-1418.
8. Gabrielsson J and Weiner D (2000) Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, 3rd ed. Swedish Pharmaceutical Press, Stockholm, Sweden. Goulart BH, Clark JW, Pien HH, Roberts TG, Finkelstein SN, and Chabner BA (2007)Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res 13:6719-6726.
9. Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, and Ciardiello F (2014) ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev 40:300-306.
10. Johnson TW, Richardson PF, Bailey S, Brooun A, Burke BJ, Collins MR, Cui JJ, Deal JG, Deng YL, Dinh D, et al. (2014) Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem 57:4720-4744.
11. Jusko WJ and Ko HC (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56:406-419.
12. Lesko LJ, Rowland M, Peck CC, and Blaschke TF (2000) Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res 17:1335-1344.
13. Le Tourneau C, Lee JJ, and Siu LL (2009) Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101:708-720.
14. Meric-Bernstam F, Farhangfar C, Mendelsohn J, and Mills GB (2013) Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol 31:1849-1857.
15. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, et al. (2008) Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 14:7917-7923.
16. Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, Tyson L, Pao W, Rizvi NA, Schwartz LH, et al. (2007) Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13:5150-5155.
17. Rosell R, Karachaliou N, Morales-Espinosa D, Costa C, Molina MA, Sansano I, Gasco A, Viteri S, Massuti B, Wei J, et al. (2013) Adaptive resistance to targeted therapies in cancer. Transl Lung Cancer Res 2:152-159.
18. Sharma A, Ebling WF, and Jusko WJ (1998) Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci 87:1577-1584.
19. Sheiner LB, Stanski DR, Vozeh S, Miller RD, and Ham J (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25:358-371.
20. Soria JC, Mok TS, Cappuzzo F, and Jänne PA (2012) EGFR-mutated oncogene-addicted nonsmall cell lung cancer: current trends and future prospects. Cancer Treat Rev 38:416-430.
21. Stroh M, Duda DG, Takimoto CH, Yamazaki S, and Vicini P (2014) Translation of anticancer efficacy from nonclinical models to the clinic (Abstract). CPT Pharmacometrics Syst Pharmacol 3:e128.
22. Wählby U, Jonsson EN, and Karlsson MO (2001) Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28:231-252.
23. Yamazaki S (2013) Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib. AAPS J 15:354-366.
24. Yamazaki S, Lam L, Helen Y, Zou HY, Smeal T, and Vicini P (2014) Pharmacokineticpharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase inhibition and c-Ros oncogene 1. J Pharmacol Exp Ther 351:67-76.
25. Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, Koup JR, Smith BJ, and Koudriakova T (2008) Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos 36:1267-1274.
26. Yamazaki S, Vicini P, Shen Z, Zou HY, Lee J, Li Q, Christensen JG, Smith BJ, and Shetty B (2012) Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. J Pharmacol Exp Ther 340:549-557.
27. Zou HY, Engstrom L, Li Q, Lu MW, Tang RW, Wang H, Timofeevski S, Lam J, Yamazaki S, Hu W, et al. (2013) PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1G2032R mutant in preclinical tumor models. Proceedings of the AACR Annual Meeting; 2013 Apr 6-10; American Associations for Cancer Research, Washington, DC.